vimarsana.com

Latest Breaking News On - Surface oncology - Page 10 : vimarsana.com

FDA partially halts leukemia studies of Gilead cancer drug

BioPharma

Calistoga pharmaceuticalsBoehringer ingelheimDrug administrationBristol myers squibbGilead sciencesDive briefSurface oncologyForty sevenKite pharmaArcus biosciencesClinical trials

SHAREHOLDER ALERT: Weiss Law Investigates Surface Oncology, Inc

SHAREHOLDER ALERT: Weiss Law Investigates Surface Oncology, Inc.

New yorkUnited statesJoshua rubinCoherus biosciences incNews networkSurface oncology incWeiss lawSurface oncologyCoherus biosciences

Vaccinex Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Phase 1/2a SIGNAL-AD Study of Pepinemab in Alzheimer’s Disease Achieves Full Accrual Expect to Complete 12-months treatment in June, 2024 Promising Interim Results for KEYNOTE-B84 Phase 2 Trial. -Today at 08:11 am- MarketScreener

United statesAlbertd friedbergVaccinex rochesterJohn mullalyMaurice zaudererExchange commissionAlzheimer drug discovery foundationPlatform technologyVaccinex incCo incUniversity of rochesterCoherus biosciences incMerck kgaAlzheimer associationUniversity of rochester cancer centerLifesci advisors

Vaccinex Reports Second Quarter 2023 Financial Results and Provides Corporate Update - Vaccinex (NASDAQ:VCNX)

Phase 1/2a SIGNAL-AD Study of Pepinemab in Alzheimer's Disease Achieves Full Accrual Expect to Complete 12-months treatment in June, 2024 Promising Interim Results for KEYNOTE-B84 Phase 2 Trial in Head and Neck Cancer

United statesVaccinex rochesterAlbertd friedbergJohn mullalyMaurice zaudererAlzheimer associationVaccinex incCo incMerck coCoherus biosciences incExchange commissionUniversity of rochester cancer centerLifesci advisorsMerck kgaaUniversity of rochesterMoffitt cancer center

Why Coherus BioSciences Stock Popped Today

The immuno-oncology leader delivered a strong second quarter.

Denny lanfearCoherus biosciencesSurface oncology

vimarsana © 2020. All Rights Reserved.